XML 26 R14.htm IDEA: XBRL DOCUMENT

Investments

9 Months Ended

Mar. 31, 2019

Equity Method Investments and Joint Ventures [Abstract]

NOTE 7 – INVESTMENTS

Ankang Longevity Group entered into two equity investment agreements with Shaanxi Pharmaceutical Group Pai'ang Medicine Co. Ltd. ("Shaanxi Pharmaceutical Group"), a Chinese state-owned pharmaceutical enterprise to invest a total of RMB 6.8 million (approximately US$ 1.0 million) for a 49% equity interest in a pharmacy retail company called Shaanxi Pharmaceutical Sunsimiao Drugstores Ankang Retail Chain Co., Ltd. ("Sunsimiao Drugstores"), and a 49% equity interest in a pharmaceutical wholesale distribution company named Shaanxi Pharmaceutical Holding Group Longevity Pharmacy Co., Ltd. ("Shaanxi Longevity Pharmacy"). These two equity investments were formed as new business entities to collaborate with Shaanxi Pharmaceutical Group to expand sales to regional hospitals and clinics and to establish the presence of retail pharmacies under the Brand name "Sunsimiao". The investments are accounted for using the equity method because Ankang Longevity Group has significant influence, but no control of these two entities. Ankang Longevity Group recorded income of US$ 421,115 and US$ 550,759 for the nine months ended March 31, 2019 and 2018, respectively and recorded income of US$ 132,238 and US$ 200,107 for the three months ended March 31, 2019 and 2018, respectively, from the investments, which was included in "Income from equity method investments" in the unaudited condensed consolidated statements of income and comprehensive income (see Note 11).

Ankang Longevity Group entered into a supplemental agreement with Shaanxi Pharmaceutical Group. According to the supplemental agreement, new 49% equity investment companies established by Shaanxi Pharmaceutical Group and Ankang Longevity Group are required to exclusively purchase certain raw materials and drug products from Shaanxi Pharmaceutical Group. In return, Shaanxi Pharmaceutical Group has agreed to compensate Ankang Longevity Group with a purchase rebate of 7% of the total purchases made from Shaanxi Pharmaceutical Group. For the nine months ended March 31, 2019 and 2018, a total of US$ 812,137 and US$ 1,191,011 was recognized by Ankang Longevity Group from this supplemental agreement in addition to its 49% share of the income from the equity investment companies, respectively. For the three months ended March 31, 2019, total income of US$ 294,511 was recognized by Ankang Longevity Group from this supplemental agreement, compared to US$ 411,076 in the same period in 2018.

On October 21, 2013, the Company, through its controlled subsidiaries, Zhisheng Freight and Zhisheng Agricultural, entered into an agreement with an unrelated third party, Zhejiang Zhen'Ai Network Warehousing Services Co., Ltd. ("Zhen'Ai Network"), and invested RMB 14.5 million (approximately US$ 2.2 million) into Tiancang Systematic Warehousing project ("Tiancang Project") operated by Zhen'Ai Network. The Tiancang Project is an online platform established to provide comprehensive warehousing and logistic solutions to companies involved in E-commerce. The Company is entitled to 29% of Tiancang Project's after-tax net income annually, less 30% statutory reserve and a 10 % employee welfare fund contribution. When the amount of the accumulated statutory reserve reaches 30% of the total investment for the Tiancang Project, no additional appropriation to the statutory reserve is required. For the nine and three months ended March 31, 2019, the Company didn't record any investment income distribution from Zhen'Ai Network. And for the nine and three months ended March 31, 2018, the Company recorded investment income distributions of US$ 152,694 from Zhen'Ai Network.

On November 21, 2016, the Company (the "Investor") entered into an agreement with Original Lab Inc., a California corporation (the "Investee"), and made a payment of US$ 200,000 in exchange for the right to acquire certain shares of the Investee's common and preferred stock. For the nine and three months ended March 31, 2019 and 2018, the Company did not record investment income from this investment.

The Company's investments in unconsolidated entities consist of the following:

		March 31, 2019				June 30, 2018

Shaanxi Pharmaceutical Holding Group Longevity Pharmacy Co., Ltd. (Ankang Longevity Pharmacy)		$	3,722,450			$	3,439,793
Shaanxi Pharmaceutical Sunsimiao Drugstores Ankang Chain Co., Ltd.			820,742				736,898
Zhejiang Zhen'Ai Network Warehousing Services Co., Ltd.			2,160,595				2,190,399
Original Lab Inc.			200,000				200,000
Total		$	6,903,787			$	6,567,090

Summarized financial information of unconsolidated entities is as follows:

		March 31, 2019				June 30, 2018

Current assets		$	39,603,257			$	38,079,702
Noncurrent assets			250,232				291,267
Current liabilities			30,597,013				29,862,664

		For the nine months ended March 31,
		2019				2018

Net sales		$	17,361,229			$	28,482,180
Gross profit			2,530,383				3,549,739
Income from operations			943,233				1,225,896
Net income			870,821				1,123,997